Interview with Linden Thomson, Axa IM

Linden Thomson, lead manager of the Axa IM Framlington Biotech fund, tells Natalie Kenway that after extremely low investor sentiment towards the sector at the start of 2022, the fundamentals for biotech investing have greatly improved.

Equities